Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary...

Area of Science:

• Cardiology
• Immunology
• Surgical Innovation

Background:

• Coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass can lead to inflammation and ischemia-reperfusion injury.
• These complications are associated with increased risk of postoperative myocardial infarction (MI) and mortality.

Purpose of the Study:

• To evaluate the efficacy and safety of pexelizumab, a C5 complement inhibitor, in mitigating perioperative MI and mortality in patients undergoing CABG surgery.
• To determine if pexelizumab can reduce adverse cardiovascular events following CABG procedures.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 3099 adult patients undergoing CABG surgery (with or without valve surgery).
• Patients received either intravenous pexelizumab or a placebo before surgery.
• The primary composite endpoint was death or MI within 30 days in patients undergoing CABG surgery only; intent-to-treat analyses included all patients.

Main Results:

• In the CABG-only group (n=2746), pexelizumab did not significantly reduce the composite endpoint of death or MI (9.8% vs 11.8%, P=.07).
• In the intent-to-treat analysis of all patients (n=3099), pexelizumab was associated with a statistically significant reduction in death or MI at 30 days (11.5% vs 14.0%, P=.03).
• The trial was not powered to detect a significant reduction in mortality alone.

Conclusions:

• Pexelizumab did not demonstrate a significant reduction in the composite endpoint of death or MI for patients undergoing CABG surgery alone.
• However, pexelizumab showed a statistically significant benefit in reducing the composite endpoint of death or MI in the overall study population undergoing CABG with or without valve surgery.
• Further research may be needed to clarify the role of C5 inhibition in cardiac surgery outcomes.